Abstract
Migraine shows a higher prevalence in women especially during reproductive age. Over 50% of patients report a higher occurrence of migraine attacks during perimenstrual window. Menstrual migraine attacks are referred as more disabling, less responsive to symptomatic treatments, longer in duration, and more prone to relapse than non-menstrual migraine attacks. Several evidences suggest that estrogen fluctuations are involved in migraine attacks worsening during the perimenstrual window through several mechanisms involving CGRP pathway. We aimed to evaluate whether mAbs blocking CGRP-ligand or receptor (CGRP-mAbs) could represent an effective and safety preventive treatment for menstrual migraine attacks in patients with menstrual related migraine (MRM) with previous treatment failures.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
